Logo (Actavis) 422 Pill - gray round, 8mm
Pill with imprint Logo (Actavis) 422 is Gray, Round and has been identified as Lamotrigine Extended-Release 100 mg. It is supplied by Actavis Pharma, Inc.
Lamotrigine is used in the treatment of Bipolar Disorder; Lennox-Gastaut Syndrome; Epilepsy; Seizure Prevention; Seizures and belongs to the drug class triazine anticonvulsants. Risk cannot be ruled out during pregnancy. Lamotrigine 100 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Logo (Actavis) 422
Lamotrigine Extended-Release
- Imprint
- Logo (Actavis) 422
- Strength
- 100 mg
- Color
- Gray
- Size
- 8.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Triazine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Actavis Pharma, Inc.
- National Drug Code (NDC)
- 00228-1422
- Inactive Ingredients
-
hypromelloses,
lactose monohydrate,
magnesium stearate,
methacrylic acid - methyl methacrylate copolymer (1:2),
silicon dioxide,
magnesium silicate,
titanium dioxide,
triethyl citrate,
FD&C Blue No. 2,
FD&C Red No. 40,
FD&C Yellow No. 6,
triacetin
Note: Inactive ingredients may vary.
More about lamotrigine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,766)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: triazine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Lamotrigine drug information
- Lamotrigine Chewable Dispersible Tablets
- Lamotrigine Orally Disintegrating Tablets
- Lamotrigine Extended-Release Tablets
- Lamotrigine Tablets
Other brands
Lamictal, Lamictal XR, Subvenite, Lamictal ODT, Lamictal CD
Professional resources
- Lamotrigine monograph
- Lamotrigine (FDA)
- Lamotrigine Chewable Tablet (FDA)
- Lamotrigine Extended Release Tablet (FDA)
- Lamotrigine ODT (FDA)
- Lamotrigine Tablets (FDA)
Other brands
Lamictal, Lamictal XR, Subvenite
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
